The Chinese Pharmaceuticals Market to 2024

 Published On: Mar, 2014 |    No of Pages: 160 |  Published By: GMR Data | Format: PDF
Download Free Sample

Commercial & Strategic developments in the Chinese Pharmaceutical Market to 2024

- Capture or increase your foothold in the Chinese market TODAY
- Establish partnerships to manufacture, distribute or develop Chinese products
- Establish anti-counterfeiting systems today to increase market size and revenue

From 2008 to 2013, China’s OTC drugs market reported an average growth of 15% with the market reaching $20.6bn in 2013 up from to $11bn in 2008 - but what will it be this year? Next year? and in 5 years time?

The OTC drugs market in China was characterised by a late start, but fast growth, along with huge potential in comparison to that of the mature OTC markets in many western countries. Your company should be benefiting from this market access – and this is only the OTC market – what has the growth been throughout the whole Chinese pharma sector? This report will tell you.

China’s pharmaceutical sales growth is based on economic growth in the country: This has resulted in increased healthcare expenditure internally, and increased manufacture and export. Increasing urbanisation, disposable income, aging population, health education, lifestyle diseases and government investments and initiatives for healthcare infrastructure improvement have helped the market growth considerably. Have you captured enough of the Chinese market?

Annually, an average of $190 is spent for the treatment of diabetes, per patient, in China. By 2030, in China, diabetes is expected to cost Yuan 173.4bn ($28 bn) a year. China is expected to top the world’s diabetes tables both in terms of sheer numbers and population prevalence. This is true across a range of complaints and products types – your company must capture a segment of this market TODAY.

Anti-Counterfeiting and anti-corruption – How the Chinese market is changing
Counterfeit drugs are successfully introduced in to the lengthy and complicated delivery chain because of the highly fragmented nature of the market. A lack of regular inspections by any recognised drug enforcement / regulatory bodies, again due to the highly fragmented nature of production, allows counterfeit / poor quality drugs into the Chinese pharma market. Moreover, wide spread corruption also helps the distribution of counterfeit drugs. What are the Chinese regulators, and the global manufacturers doing to change this? Find out in this unique report.

Increased inward investment from multiple ‘Big Pharma’ companies has driven investment in R&D centres as well as opportunities for Chinese graduates. Many graduates are staying in China; those that have left now have jobs to return to. Are you producing enough of your products in China? Increase your profitability through this channel.

Domestically, increased levels of health insurance, increased health education, rising numbers of hospitals and increased per capita income have all driven the Chinese pharmaceutical market.

Increase in healthcare expenditure per capita, from $157in 2008 to $278 in 2011
Increasing income and population. The middle class population reached 400m in 2010 and is expected to reach 500m by 2015
In 2012, the central government alone invested CNY 24.3bn ($3.9bn) to improve health service infrastructure.
Key life style changes, which have accelerated the diseases such as obesity, diabetes, cardiovascular, chronic respiratory diseases
The over 65 population has increased to 9.1% of the total population in China in 2011 from 8.3% in 2008

This report also breaks down the market in terms of current drugs and products that occupy the Chinese market at present; examining the key prescription and OTC drugs that drive the Chinese market. In addition to this crucial information this report offers analysis and opinion on current R&D in the country alongside in depth analysis of the evolving, global inward investment.

Discover exactly what the industry leaders are doing TODAY -

Industry information sourced exclusively for this report. This information is not available anywhere else

Utilising primary and secondary research sources, GMR Data have interviewed leading specialists within big pharma, R&D, wholesalers, distributors, marketeers and key organisations specialising in access to the Chinese market, as well as Chinese pharmaceutical companies accessing the global market. From these interviews we have selected original, exclusive, transcribed interviews with leading specialists in their field – This information is not available anywhere else.

This GMR Data report is the single tool to equip you with the latest trends in all pharma sectors and why all stakeholders demand development of the Chinese pharmaceutical market. This report will arm you with all you and your company require to develop, price, launch and market a product in China, or compete with a Chinese product launched in your market.

Companies Mentioned in this report

Abbott Laboratories and Takeda Pharmaceutical Co Ltd
Alcon
Alliance Boots GmbH
Amgen
Ascendancy Healthcare
Ascletis
AstraZeneca
Bayer Healthcare
BeiGene Ltd
Beijing Drug Administration
Beijing Montagne Medical Device Co., Ltd
Beijing Percil Instrument
Beijing University
BioMatrix
Biosensors Europe S.A.
Biosensors International Group, Ltd.
BMS
Boehringer Ingelheim
Celsion
Changzhou Kony Pharmaceutical Co., Ltd
Changzhou Pharmaceutical Incorporated
Charles River
China Resources Double Crane Pharmaceutical Co., Ltd
China Resources Sanjiu Pharmaceutical
China Shijiazhuang Pharmaceutical Group Co., Ltd (CSPC)
Ciba - Geigy Pharmaceutical Co., Ltd
Colgate-Palmolive Co
Concord Medical Services Holdings Limited
Covance
CSPC Huasheng Pharma
CSPC XNW Pharmaceutical Joint Stock Co., Ltd
CSPC Zhongrun Pharmaceutical Co. Ltd
Daiichi Sankyo
Dainippon Sumitomo Pharma
Eddingpharm
Eisai China Inc
Eisai Co., Ltd
FibroGen
Fudan University
GE Healthcare
GlaxoSmithKline
Grandhope Biotech
Guangzhou Pharma
Hangzhou East China Pharmaceutical Group
Hangzhou Optcla Medical Instrument
Hangzhou Tigermed Consulting
Harbin Pharmaceutical
Harbin Pharmaceutical Group Holding Co., Ltd
Hawley & Hazel (BVI) Co. Ltd.
Hisor
Hua Medicine Ltd
ICON
Innovation Centre China (ICC)
Ironwood Pharmaceuticals
Japan's Pharmaceuticals and Medical Devices Agency (PMDA)
Jiangsu Hengrui Medicine Co., Ltd
Johnson & Johnson
JOINN Laboratories
Jointown
Journal of Toxicology and Environmental Health
JW MedicalSystems Ltd
Kanghui Holdings
KangHui Medical
Kyowa Hakko Kirin Co.
LifeTech
Livzon Pharmaceutical Group Inc.
Medtronic
Merck & Co.
Merck Sharp & Dohme (China) Co. Ltd
MicroPort Scientific Corporation
Mindray
Nanjing MeiRui Pharma Co.
Nanjing Pharmaceutical Co.
Neptune Interlong Bio-Technique Co. Ltd. (NIBT)
NeuroVive Pharmaceutical AB
North China Pharmaceutical Group Corp (NCPC)
NovaMed
Novartis
Orchid Chemicals and Pharmaceuticals Limited
Peking University
Pfizer
Philips Electronics NV.
Philips Healthcare
Procter & Gamble Co.
ProteoTech
ProteoTech
Qianjin Pharmacy
Qidong Gaitianli Pharmaceutical
Quintiles
Roche
Sanofi- Aventis
SFDA
Shandong University
Shandong Weigao
Shandong Xinhua Pharmaceutical Company Limited
Shanghai Apex Electronics
Shanghai ChemPartner
Shanghai Institutes for Biological Sciences of Chinese Academy of Science
Shanghai Jiaotong University
Shanghai Jinhe Bio-Technology Co., Ltd
Shanghai Medical Optical Instrument
Shanghai New Hongqiao International Medical Center
Shanghai Pharmaceuticals
Shanghai Roche Pharmaceutical Co., Ltd.
Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd.
ShangPharma
Shenzhen GSK-Neptunus Biologicals Co. Ltd
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd
Shijiazhuang Lerentang Pharmaceutical Co.
Siemens
Siemens Healthcare Diagnostics
Siemens Hearing Instrument (Suzhou)
Siemens Medical Solutions Diagnostics Ltd
Siemens Mindit Magnetic Resonance (SMMR)
Siemens Shanghai Medical Equipment (SSME)
Siemens X-Ray Vacuum Technology (Wuxi)
Sihuan Pharmaceutical Holdings
Simcere Pharmaceutical Group (SCR)
Sino Biological and Pharmaron
Sinopharm
Spectrum Dynamics Medical, Inc.
Stryker
Synthes
Takeda (China) International Trading Co., Ltd
Tasly Group
Tianjin Tasly Pharmaceutical
Topsun Science and Technology
Trauson Holdings
Tsinghua University
Unilever Group
FDA
Vital River
Weihai Medical Polymer Co., Ltd
Wuhan Dragonbio
WuXi Apptec
Wyeth
X-Body Biosciences
Xian Janssen Pharmaceutical Ltd
Xiuzheng Pharmaceutical
Yunnan Baiyao Group
Zhejiang Beta Pharma
Zhejiang Hisun Pharmaceutical Co
Zhejiang Huahai
Zhejiang Tianyuan
Zimmer Holdings Inc.
Zonare Medical Systems

1. Executive Summary
1.1. Chinese Pharmaceutical Market Review
1.2. Chapter Breakdown
1.3. Research and Analysis Methods

2. Drivers & Restraints of the Chinese Pharmaceutical Market
2.1 An Ageing Population will drive pharmaceutical market growth in China
2.2 Increase in Chinese urbanisation
2.3 Increase in Healthcare expenditure will increase drug demand in China
2.4 Government policies and changing environment for MNCs in China
2.5 Increased demand for improved drug quality
2.6 Healthcare Reform in China
2.7 Path to privatization of Chinese healthcare
2.8 Consolidation of the pharmaceutical distribution industry in China
2.9 Increase in lifestyle related diseases
2.10 Biotechnology Market: The Strategic Industry for China
2.11 Focus on GMP leads to Quality and Compliance reforms
2.12 Government led initiatives to attract foreign players
2.13 Talent Pool Availability
2.14 Increased Outsourcing of Drug Discovery boosting the Chinese CRO Market
2.15 Regulatory Environment
2.15.1 Drug filing
2.15.2 Advertisements
2.15.3 Drugs Pricing & Reimbursement
2.16 Traditional Chinese Medicine

3. China Pharmaceutical Market Forecast
3.1 Chinese Pharmaceutical Market; Pharmaceutical Sales (OTC and Prescription market)
3.1.1 Chinese pharmaceutical sales market Forecast 2008-2024
3.1.2 China Pharmaceutical Sales Market by Generic and Patented Drug Sales
3.1.3 Generic Drugs Market in China
3.2 The Chinese Patented Drugs Market
3.3 China Pharmaceutical Sales Market by Prescription and OTC Drug Sales
3.3.1 Prescription Drug Market in China
3.3.2 Over-the-Counter Drugs Market in China

4. The Chinese Medical Device Market
4.1 Overview of the Medical Device Market in China
4.2 China Medical Devices Market: Diagnostic Imaging Segment
4.3 China Medical Devices Market: Patient Aids Segment
4.4 China Medical Devices Market: Consumables Segment
4.5 The China Medical Devices Market: Dental Segment
4.6 China Medical Devices Market: Orthopaedic Segment
4.7 Challenges & Opportunities in the Medical devices market
4.7.1 Opportunities
4.7.2 Challenges
4.8 China Medical Devices Market: Players Landscape
4.8.1 Multinational Corporations in the Chinese Medical devices market
4.8.1.1 General Electric Healthcare
4.8.1.1 Medtronic, Inc.
4.8.1.2 Zimmer - Zimmer Holdings, Inc.
4.8.1.3 Stryker Corporation
4.8.1.4 Siemens Healthcare
4.8.1.5 Johnson & Johnson
4.8.1.6 Philips Healthcare (Suzhou) Co., Ltd
4.9 Key Domestic companies in the Chinese Medical devices market
4.9.1 Weigao group
4.9.2 Mindray Medical International Limited
4.9.3 MicroPort Scientific Corporation
4.9.4 Biosensors International Group, Ltd

5. The Chinese API Market
5.1 API Overview
5.1.1 Global API Market
5.1.1.1 APAC API Market
5.1.1.2 The Chinese API Market
5.2 Major Growth Drivers for the Chinese API Market
5.3 Key Challenges
5.4 China API Market: Players Landscape
5.4.1 Major Chinese API Manufacturers
5.4.1.1 Zhejiang Hisun Pharmaceutical Co. Ltd
5.4.1.2 Jiangsu Hengrui Medicine Co., Ltd
5.4.1.3 CSPC Pharmaceutical Group Limited
5.4.1.4 Shandong Xinhua Pharmaceutical Company Limited
5.4.1.5 Shanghai Pharma Holding Company Limited
5.4.1.6 North China Pharmaceutical Group Corp.

6 Key Chinese Therapeutic Markets
6.1 Cardiovascular Diseases
6.1.1 Chinese Cardiovascular Disease treatments market forecast 2014-2024
6.2 Infectious Diseases
6.2.1 Chinese Infectious Disease treatments market forecast 2014-2024
6.3 Oncology
6.3.1 Chinese Oncology treatments market forecast 2014-2024
6.4 Nervous System
6.4.1 The Chinese Nervous System market forecast 2014-2024
6.5 Alimentary Tract & Metabolism
6.5.1 The Chinese Alimentary Tract & Metabolism treatments market forecast 2014-2024

7. Major Players
7.1 Pfizer
7.2. Bayer
7.3. Sanofi-Aventis
7.4. AstraZeneca
7.5. Roche
7.6. Merck and Co.
7.7. Novartis
7.8. GSK
7.9. Novo Nordisk (Novo Nordisk (China) Pharmaceutical Co., Ltd.)

8. Expert Opinion
8.1 Dr Cezary Statuch – Vice President Bristol-Myers Squibb, China
8.2 Dr Eugene Buff – Primary Care Innovation Consulting & UsTech Discovery LLC

List of Tables

Table 2.1.1: Percentage of Chinese population aged 60 and over / 65 and over in 2000, 2011 & 2016
Table 2.1.2: Health spending in China, India and the US, 2009 & 2011 ($/p/a & percentage change)
Table 2.1.3: Total Health Expenditure (as % of GDP); Selected Countries 2004 to 2011
Table 2.1.4: Life expectancy; Selected Countries 2004 to 2011
Table 2.2.1 Medical Coverage for Rural / Urban inhabitants in China 2006 / 2009 (million people)
Table 2.2.2: Major cities in China by population (2011)
Table 2.3.1 China’s Health Care Expenditure Per Capita 2003-2011
Table 2.6.1: Key New Drugs on the 2012 Essential Drugs List
Table 2.8.1: Total Revenue of Key Chinese Pharmaceutical Distribution Companies, 2012 ($/bn)
Table 2.9.1: Number of Patients with Diabetes in China
Table 2.15.3.1 China healthcare payment source breakdown 2000, 2005 & 2010 (%)
Table 3.1.1.1: China Pharmaceutical Sales Market Size: 2008-2013 ($bn)
Table 3.1.1.2: China Pharmaceutical Sales Market Forecast 2014-2024 ($bn)
Table 3.1.3.1: China Generic Drug Sales Market Size: 2008-2013
Table 3.1.3.2: China’s Generic Drug Sales Market Forecast 2014-2024 ($bn)
Table 3.2.1: China Parented Drug Sales Market Size: 2008-2013
Table 3.2.2: China Patented Drug Sales Market Forecast 2014-2024 ($bn)
Table 3.3.1.1: China Prescription Drugs Sales Market Size: 2008-2013
Table 3.3.1.2: China Prescription Drug Sales Market Size: 2014-2024
Table 3.3.2.1: China OTC Drug Sales Market Size: 2008-2013
Table 3.3.2.2 China’s OTC Drug Sales Percentage 2013
Table 3.2.2.3: China OTC Drug Sales Market Size: 2014-2024
Table 4.a: The Chinese Medical Devices Market Forecast 2014 -2024, by device type ($/bn)
Table 4.b: Key Device Segments CAGR 2014-2024 (%)
Table 4.c: Estimated China Medical Devices Market Share for Selected Segments 2014, 2019 and 2024 (%)
Table 4.1.1: China Medical Devices Market Size: 2008-2013
Table 4.1.2: China Medical Devices Export Market 2009-2011 ($/bn)
Table 4.1.3: China Medical Devices Import Market
Table 4.1.4: China Medical Devices Market Forecast 2014-2024 ($bn)
Table 4.2.1: China Medical Devices Market: Diagnostic Imaging Segment 2008-2013 ($/bn)
Table 4.2.2: China Medical Devices Market: Diagnostic Imaging Segment Forecast 2014-2024 ($/bn)
Table 4.3.1: China Medical Devices Market: Patient Aids Segment 2008-2013 ($/bn)
Table 4.3.2: China Medical Devices Market: Patient Aids Segment Forecast 2014-2024 ($/bn)
Table 4.4.1: China Medical Devices Market: Consumables Segment 2008-2013 ($/bn)
Table 4.4.2: The Chinese Medical Devices Market: Consumables Segment Forecast 2014-2024 ($ bn)
Table 4.5.1: China Medical Devices Market: Dental Segment 2008-2013
Table 4.5.2: China Medical Devices Market: Dental Segment Forecast 2014-2024 ($m)
Table 4.6.1: China Medical Devices Market: Orthopaedic Segment 2008-2013
Table 4.6.2: China Medical Devices Market: Orthopaedic Segment Forecast 2014-2024 ($m)
Table 5.1: China API Market Forecast 2014 -2024, compared to Global API Market ($ bn)
Table 5.1.1.: China API Market Size: 2009-2013
Table 5.1.2: China API Market Forecast 2014-2024 ($bn)
Table 6.a: China Pharmaceutical Market by Therapeutic Areas 2014 -2024, ($ bn)
Table 6.b: Key Therapeutic Areas CAGR 2014-2024 (%)
Table 6.c: Estimated China Pharmaceutical Market Share by Therapeutic Areas - 2014, 2019 and 2024 (%)
Table 6.1.1: Cardiovascular Disease Incidence China 2010 – 2013
Table 6.1.2: Deaths due to Cardiovascular Disease in India, China and Developed Markets
Table 6.1.3: China Pharmaceutical Market for Cardiovascular Disease, 2008 – 2013 ($/bn)
Table 6.1.4: China Pharmaceutical Market for Cardiovascular Disease: Forecast 2014 – 2024
Table 6.2.1: Infectious Disease Incidence 2010 – 2013
Table 6.2.2: Infectious Disease Mortality 2010 – 2013
Table 6.2.3: China Pharmaceutical Market for Systemic Anti-Infective, 2008 – 2013
Table 6.2.4: China Pharmaceutical Market for Systemic Anti-Infective: Forecast 2014 – 2024
Table 6.3.1: Cancer Incidence China 2010 – 2013
Table 6.3.2: Cancer Mortalities 2010 – 2013
Table 6.3.3: China Pharmaceutical Market for Oncology, 2008 – 2013
Table 6.3.4: China Pharmaceutical Market for Oncology: Forecast 2014 – 2024
Table 6.4.1: China Pharmaceutical Market for Central Nervous System, 2008 – 2013
Table 6.4.2: China Pharmaceutical Market for Central Nervous System: Forecast 2014 – 2024
Table 6.5.1: China Pharmaceutical Market for Metabolism, 2008 – 2013
Table 6.5.2: China Pharmaceutical Market for Metabolism: Forecast 2014 – 2024

List of Figures

Figure 2.1.1: China population growth trend 1950-2013
Figure 2.1.2: Projected comparison of China’s population vs. other heavily populated countries 2016 (million people)
Figure 2.1.3: China’s Age distribution: 2001 to 2011
Figure 2.1.4: Life expectancy in China
Figure 2.2.1: China’s Rural and Urban population from 1990 to 2025 – Billion People
Figure 2.2.2: China’s Urbanisation Rate 1990-2025 (%)
Figure 2.2.3: Per Capita Disposable Income
Figure 2.3.1: China GDP growth trend (2004 – 2012)
Figure 2.3.2: China’s total health expenditure (as % of GDP): 2004 to 2011
Figure 2.3.3: China healthcare expenditure per capita growth trend (2003 – 2011)
Figure 2.6.1: China’s 2009 health care reform – Healthcare package breakdown
Figure 2.8.1: Chinese pharmaceutical distribution sales: 2006 to 2012
Figure 2.9.1: Number of Patients with Diabetes in 2013 – Globally (million people)
Figure 2.13.1: China’s talent pool in 2010- (in millions)
Figure 2.15.3.1: China healthcare payment source breakdown
Figure 3.1.1: China Pharmaceutical Sales Market Size: 2008-2013
Figure 3.1.2: China Pharmaceutical Sales Market Forecast 2014-2024 ($bn)
Figure 3.1.3.1: China Generic Drug Sales Market Size: 2008-2013
Figure 3.1.3.2: China’s Generic Drug Sales Market Forecast 2014-2024 ($ bn)
Figure 3.2.1: China Patented Drug Sales Market Size: 2008-2013
Figure 3.2.2: China Patented Drug Sales Market Forecast 2014-2024 ($ bn)
Figure 3.3.1.1: China Prescription Drug Sales Market Size: 2008-2013
Figure 3.3.1.2: China Prescription Drug Sales Market Size: 2014-2024
Figure 3.3.2.1: China OTC Drug Sales Market Size: 2008-2013
Figure 3.3.2.2 OTC drugs Channel Breakdown in China 2011
Figure 3.2.2.3: China OTC Drug Sales Market Size: 2014-2024
Figure 4.a: China Medical Devices Market Share for Selected Segments 2014
Figure 4.b: China Medical Devices Market Share for Selected Segments 2019
Figure 4.c: China Medical Devices Market Share for Selected Segments 2024
Figure 4.1.1: China Medical Devices Market Size: 2008-2013
Figure 4.1.2: China Medical Devices Market Forecast 2014-2024 ($bn)
Figure 4.2.1: China Medical Devices Market: Diagnostic Imaging Segment 2008-2013
Figure 4.2.2: China Diagnostic Imaging devices breakdown by sub-segment, 2012 (%)
Figure 4.2.3: China Medical Devices Market: Diagnostics Segment Forecast 2014-2024 ($bn)
Figure 4.3.1: China Medical Devices Market: Patient Aids Segment 2008-2013 ($/bn)
Figure 4.3.2: 2012 Patient Aids devices breakdown by sub-segment 2012 (%)
Figure 4.3.3: China Medical Devices Market: Patient Aids Segment Forecast 2014-2024 ($/bn)
Figure 4.4.1: China Medical Devices Market: Consumables Segment 2008-2013
Figure 4.4.2: 2012 Consumables devices breakdown by sub-segment
Figure 4.4.3: China Medical Devices Market: Consumables Segment Forecast 2014-2024 ($ bn)
Figure 4.5.1: China Medical Devices Market: Dental Segment 2008-2013
Figure 4.5.2: 2012 Dental Devices breakdown by sub-segment, China, 2013
Figure 4.5.3: China Medical Devices Market: Dental Segment Forecast 2014-2024 ($m)
Figure 4.6.1: China Medical Devices Market: Orthopaedic Segment 2008-2013
Figure 4.6.2: 2012 Orthopaedic Devices breakdown by sub-segment
Figure 4.6.3: China Medical Devices Market: Orthopaedic Segment Forecast 2014-2024 ($m)
Figure 4.8.1.2.1: Medtronic 2012 Customer base breakdown by region
Figure 4.9.1.1: 2012 Customer base breakdown by segment
Figure 4.9.1.2: 2012 Sales revenue breakdown by region
Figure 4.9.1.3: Weigao Group Sales revenue breakdown by product segment 2012 (%)
Figure 4.9.2.1: 2012 Sales revenue breakdown by region
Figure 4.9.2.2: 2012 Sales revenue breakdown by product
Figure 4.9.3.1: 2012 Sales revenue breakdown by product (%)
Figure 4.9.4.1: 2012 Sales revenue breakdown by product (%)
Figure 5.1.1.1: Breakdown of API Manufacturing 2012
Figure 5.1.1.2.1: China API Market Size: 2009-2013
Figure 5.1.1.2.2: China API Market Breakdown 2013
Figure 5.1.1.2.3: China API Market Forecast 2014-2024 ($bn)
Figure 6.a: China Pharmaceutical Market Share by Therapeutic Areas 2014
Figure 6.b: China Pharmaceutical Market Share by Therapeutic Areas 2019
Figure 6.c: China Pharmaceutical Market Share by Therapeutic Areas 2024
Figure 6.1.1: Cardiovascular Disease Incidence 2010 – 2013
Figure 6.1.2: China Pharmaceutical Market for Cardiovascular Disease, 2008 – 2013 ($/bn)
Figure 6.1.3: China Pharmaceutical Market for Cardiovascular Disease: Forecast 2014 – 2024
Figure 6.2.1: Infectious Disease Incidence 2010 – 2013
Figure 6.2.2: Infectious Disease Mortality 2010 – 2013
Figure 6.2.3: Mortality as per Infectious Diseases, China 2012
Figure 6.2.4: China Pharmaceutical Market for Systemic Anti-Infective, 2008 – 2013
Figure 6.2.5: China Pharmaceutical Market for Systemic Anti-Infective: Forecast 2014 – 2024
Figure 6.3.1: Cancer Deaths in China / Hong Kong, 2011
Figure 6.3.2: China Pharmaceutical Market for Oncology, 2008 – 2013
Figure 6.3.3: China Pharmaceutical Market for Oncology: Forecast 2014 – 2024
Figure 6.4.1: China Pharmaceutical Market for Central Nervous System, 2008 – 2013
Figure 6.4.2: China Pharmaceutical Market for Central Nervous System: Forecast 2014 – 2024
Figure 6.5.1: China Pharmaceutical Market for Metabolism, 2008 – 2013
Figure 6.5.2: China Pharmaceutical Market for Metabolism: Forecast 2014 – 2024
Figure 7.9.1 Novo Nordisk’s sales of diabetes products in China, 2012


If the above report does not have the information suitable for your business, we can provide custom research that can be lucrative for your business or enhance your profession.